Our future experiments will explore other possible pathways and related factors on the pathways to analyze the mechanism of anti-acute kidney injury of ACT and ISO, such as Slc5a2, Lcn2 and Havcr1, meanwhile, in the next study, we will also compare the ISO group with the ISO+ACT synergistic group, to further prove that the ISO has a better pharmacological effect in the treatment of acute kidney injury. The gene discussed is LCN2; the disease is acute kidney injury.